1. World Health Organization report.
https://www.who.int/data/gho/data/themes/hiv-aids. Accessed 23 Dec 2022
2. Anjum, R., & Lakshmi, P. K. (2020). Dolutegravir sodium loaded solid lipid nanoparticles: A vaginal drug delivery system for pre-exposure prophylaxis of HIV. J Res Pharm., 24(4), 552–561.
3. Venter, W. D. F., Clayden, P., & Serenata, C. (2017). The ADVANCE study: A groundbreaking trial to evaluate a candidate universal antiretroviral regimen. Current Opinion in HIV and AIDS., 12(4), 351–354. https://doi.org/10.1097/COH.0000000000000389
4. Shaikh, N. A., & Lala, R. R. (2021). Formulation development of dolutegravir sodium loaded nano lipid carriers for improved solubility and permeability. IJPSR., 12(7), 3654–3665.
5. Ghasemiyeh, P., & Mohammadi-Samani, S. (2018). Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages. Res Pharm Sci., 13(4), 288–303.